跳至主要内容
临床试验/JPRN-UMIN000041705
JPRN-UMIN000041705已完成未知

A survey of the impact of COVID-19 on the prescription and other conditions of patients with gastrointestinal diseases - A survey of the impact of COVID-19 on the prescription and other conditions of patients with gastrointestinal diseases

EA Pharma Co.,Ltd.0 个研究点目标入组 650 人开始时间: 2020年9月7日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
650

研究概览

简要总结

About 20% of eligible patients reduced their visit and 70% of them had not restored the f requency of visits. Their symptoms changed m ore widely than those who not. We identified longer duration of disease and higher medica l adherence score as the factors not reducin g visits. Few patients used telemedicine. A quarter of patients were recording their sy mptoms and they had higher medical adherence score.

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 99years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Patients who did not report any use of drugs for gastrointestinal diseases at the past survey 2. Patients who reported any cancer at the past survey 3. Patients who work for any of the following organizations - market research companies - media companies - advertising companies - hospitals or clinics - pharmaceutical companies - pharmaceutical wholesalers 4. Patients whose family members work for any of the above organizations

研究者

相似试验